Olaparib

Brand: Lynparza (global) / Olaparib (IN/BD)

Anticancer PARP inhibitor

Chemistry

Molecular Formula	C24H23FN4O3
PubChem	CID: 23725625 Open in PubChem

Structure

Half-life	12 hours
Tmax	1.5 h
Protein Binding	82 %
Volume of Distribution	1.6 L/kg (approx)
Clearance Route	hepatic
Active Metabolites	no
Notes	Avoid strong CYP3A inhibitors/inducers. Dose reduction in renal impairment.

Severity: Moderate

Adverse Effects:
Anemia, neutropenia, nausea, fatigue

Contraindications:
Severe renal impairment

Precautions:
Monitor CBC every 2–4 weeks initially
half-life ~12 hours
max dose commonly: 600 mg/day (300 mg twice daily)